Motilal Oswal's research report on Aurobindo Pharma
We analyzed the biosimilar portfolio of Aurobindo Pharma (ARBP) to understand the progress as well as competitive dynamics for each product. ARBP has built a biosimilar pipeline, which is expected to provide commercial benefit from FY26/FY27 onwards. It remains among the leading companies to gain traction in certain biosimilar products. ARBP is further enhancing benefits through CDMO partnerships and improving return on investment. On the US generics front, ARBP not only has the largest portfolio in terms of the number of molecules and revenue size, but it also continues to further enhance its offerings through aggressive filings comprising complex generics as well.
Outlook
We value ARBP at 17x 12M forward earnings to arrive at our TP of INR1,180. While the outlook is promising over the next 2-3 years, we reiterate our Neutral rating due to limited upside from current levels.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
